Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stevens-Johnson Syndrome in a Patient on Concomitant Treatment with Levetiracetam and Trimethoprim/Sulfamethoxazole.

The American journal of case reports - 22 Jan 2024

Tabet Aoul Amel, Al-Nasseri Abraheim, Hall Chase, He Chun, Abernathy John

Abstract excerpt

BACKGROUND Trimethoprim/sulfamethoxazole and levetiracetam are commonly prescribed medications in the treatment of infections and seizures, respectively. Despite their known efficacy, each has a reputation for triggering severe and sometimes life-threatening cutaneous adverse drug reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Although the mechanism of such cutaneous adverse drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Emergency Service, Hospital
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Stevens-Johnson Syndrome

Share to Trimethoprim, Sulfamethoxazole Drug Combination

Source

Open in PubMed Open full text

Identifiers

PMID: 38247161
DOI: 10.12659/AJCR.942982
PMCID: PMC10812293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stevens-Johnson Syndrome in a Patient on Concomitant Treatment with Levetiracetam and Trimethoprim/Sulfamethoxazole.PMID 38247161Read ↗

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis- An OverviewSemantic proximity Read ↗

Toxic epidermal necrolysis and Stevens-Johnson syndrome.Semantic proximity Read ↗

[Recent progress in research of pathogeneses of Stevens-Johnson syndrome and toxic epidermal necrolysis].Semantic proximity Read ↗

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisSemantic proximity Read ↗

Levetiracetam: A Possible New Inducer of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in 2 CasesSemantic proximity Read ↗

Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.Semantic proximity Read ↗

Stevens-Johnson syndrome and toxic epidermal necrolysis.Semantic proximity Read ↗

Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.Semantic proximity Read ↗

Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine.Semantic proximity Read ↗

Severe cutaneous adverse reactions to drugs.Semantic proximity Read ↗

Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.Semantic proximity Read ↗

Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.